Literature DB >> 19297028

Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.

Cristina Suárez1, Carmen Peña, Fe Tubau, Laura Gavaldà, Adriana Manzur, M Angeles Dominguez, Miquel Pujol, Francisco Gudiol, Javier Ariza.   

Abstract

OBJECTIVES: To describe the incidence and clinical characteristics of imipenem-resistant (IR) Pseudomonas aeruginosa bacteraemia.
METHODS: We performed a retrospective study including all episodes of IR P. aeruginosa bacteraemia seen from January 2003 to December 2005 in a tertiary teaching hospital.
RESULTS: There were 108 episodes of IR P. aeruginosa bacteraemia, which represented an incidence of 0.14 episodes per 1000 patient-days in 2003 and 0.11 episodes per 1000 patient-days in 2005. 83 of the episodes (77%) were nosocomially acquired. Most of patients had at least one underlying disease and had previously received antimicrobial treatment. The most frequent source was the urinary tract (31%), followed by unknown origin (22%). A total of 23 (21%) episodes were polymicrobial and 51 (47%) were caused by multidrug-resistant strains. The independent risk factors for mortality from IR P. aeruginosa bloodstream infection were a high-risk source of the bacteraemia (OR: 4.6; 95% CI 1.7-12.4; p=0.01), and presentation with severe sepsis (OR: 2.8; 95% CI 1-7.8; p=0.05).
CONCLUSIONS: Our study shows that the rates of IR P. aeruginosa bacteraemia remained stable throughout the study period. The source of bacteraemia and the clinical presentation with severe sepsis were the main determinants of the prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297028     DOI: 10.1016/j.jinf.2009.02.010

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  A sensitive fluorescence-based assay for the detection of ExoU-mediated PLA(2) activity.

Authors:  Marc A Benson; Katherine M Schmalzer; Dara W Frank
Journal:  Clin Chim Acta       Date:  2009-11-10       Impact factor: 3.786

2.  Antibacterial activity of Lawsonia inermis Linn (Henna) against Pseudomonas aeruginosa.

Authors:  O Habbal; S S Hasson; A H El-Hag; Z Al-Mahrooqi; N Al-Hashmi; Z Al-Bimani; M S Al-Balushi; A A Al-Jabri
Journal:  Asian Pac J Trop Biomed       Date:  2011-06

3.  Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.

Authors:  Mi Ae Yang; Jina Lee; Eun Hwa Choi; Hoan Jong Lee
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

4.  Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.

Authors:  Youn Jeong Kim; Yoon Hee Jun; Yang Ree Kim; Kang Gyun Park; Yeon Joon Park; Ji Young Kang; Sang Il Kim
Journal:  BMC Infect Dis       Date:  2014-03-24       Impact factor: 3.090

5.  Bacterial sepsis: challenges of diagnosis and treatment in a teaching hospital southwest of iran.

Authors:  Seyed Mohammad Alavi; Mehrdad Sharifi; Mehdi Eghtesad
Journal:  Jundishapur J Microbiol       Date:  2014-03-01       Impact factor: 0.747

6.  Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in Pseudomonas aeruginosa Bacteremia: 12-Year Experience in a Tertiary Hospital in Korea.

Authors:  Jin Suk Kang; Chisook Moon; Seok Jun Mun; Jeong Eun Lee; Soon Ok Lee; Shinwon Lee; Sun Hee Lee
Journal:  J Korean Med Sci       Date:  2021-11-08       Impact factor: 2.153

7.  Pseudomonas Aeruginosa Bacteraemia in Two UK District Hospitals.

Authors:  David A Enoch; Julie Kuzhively; Andrew Sismey; Alina Grynik; Johannis Andreas Karas
Journal:  Infect Dis Rep       Date:  2013-09-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.